12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GFT505: Phase I data

In the double-blind Phase I GFT505-109-6 trial in 30 healthy volunteers, 100 mg/day oral GFT505 significantly reduced fasting free fatty acid plasma concentration by 14% from baseline to day 14...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >